Isoform specificity of cardiac glycosides binding to human Na+,K+-ATPase α1β1, α2β1 and α3β1

被引:30
作者
Hauck, Christian [1 ]
Potter, Tatjana [1 ]
Bartz, Michaela [2 ]
Wittwer, Thorsten [5 ]
Wahlers, Thorsten [5 ]
Mehlhorn, Uwe [6 ]
Scheiner-Bobis, Georgios [2 ]
McDonough, Alicia A. [4 ]
Bloch, Wilhelm [3 ]
Schwinger, Robert H. G. [7 ]
Mueller-Ehmsen, Jochen [1 ]
机构
[1] Univ Cologne, Dept Internal Med 3, Lab Muscle Res & Mol Cardiol, D-50937 Cologne, Germany
[2] Univ Giessen, Dept Biochem & Endocrinol, Giessen, Germany
[3] German Sport Univ Cologne, Inst Mol & Cellular Sport Med, Cologne, Germany
[4] Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90033 USA
[5] Univ Cologne, Dept Cardiothorac Surg, D-50937 Cologne, Germany
[6] Johannes Gutenberg Univ Mainz, Dept Cardiothorac Surg, Mainz, Germany
[7] Klinikum Weiden, Dept Internal Med 2, Weiden, Germany
关键词
Heart failure; Digoxin; Digitoxin; beta-Acetyldigoxin; Methyldigoxin; CHRONIC HEART-FAILURE; SODIUM-PUMP ISOFORM; REGIONAL EXPRESSION; OUABAIN BINDING; YEAST-CELLS; NA; K-ATPASE; EXCHANGER; IDENTIFICATION; MYOCARDIUM; GUIDELINES;
D O I
10.1016/j.ejphar.2009.08.039
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cardiac glycosides inhibit the Na+,K+-ATPase and are used for the treatment of symptomatic heart failure and atrial fibrillation. In human heart three isoforms of Na+,K+-ATPase are expressed: alpha(1)beta(1), alpha(2)beta(1) and alpha(3)beta(1) is unknown, if clinically used cardiac glycosides differ in isoform specific affinities, and if the isoforms have specific subcellular localization in human cardiac myocytes. Human Na+,K+-ATPase isoforms alpha(1)beta(1), alpha(2)beta(1) and alpha(3)beta(1) were expressed in yeast which has no endogenous Na+,K+-ATPase. Isoform specific affinities of digoxin, digitoxin, beta-acetyldigoxin, methyldigoxin and ouabain were assessed in [H-3]-ouabain binding assays in the absence or presence of K+ (each n = 5). The subcellular localizations of the Na+,K+-ATPase isoforms were investigated in isolated human atrial cardiomyocytes by immunohistochemistry. In the absence of K+, methyldigoxin (alpha(1) > alpha(3) > alpha(2)) and ouabain (alpha(1) = alpha(3) > alpha(2)) showed distinct isoform specific affinities, while for digoxin, digitoxin and beta-acetyldigoxin no differences were found. In the presence of K+, also digoxin (alpha(2) = alpha(3) > alpha(1)) and beta-acetyldigoxin (alpha(1) > alpha(3)) had isoform specificities. A comparison between the cardiac glycosides demonstrated highly different affinity profiles for the isoforms. Immunohistochemistry showed that all three isoforms are located in the plasma membrane and in intracellular membranes, but only alpha(1)beta(1) and alpha(2)beta(1) are located in the T-tubuli. Cardiac glycosides show distinct isoform specific affinities and different affinity profiles to Na+,K+-ATPase isoforms which have different subcellular localizations in human cardiomyocytes. Thus, in contrast to current notion, different cardiac glycoside agents may significantly differ in their pharmacological profile which could be of hitherto unknown clinical relevance. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 50 条
  • [21] Na+/K+-ATPase α1 subunit, a novel therapeutic target for hepatocellular carcinoma
    Zhuang, Liping
    Xu, Litao
    Wang, Peng
    Jiang, Yan
    Yong, Pan
    Zhang, Chenyue
    Zhang, Haibin
    Meng, Zhiqiang
    Yang, Peiying
    ONCOTARGET, 2015, 6 (29) : 28183 - 28193
  • [22] AN ORGANOPHOSPHORUS COMPOUND, VX, SELECTIVELY INHIBITS THE RAT CARDIAC NA+,K+-ATPASE ALPHA-1 ISOFORM - BIOCHEMICAL BASIS OF THE CARDIOTOXICITY OF VX
    ROBINEAU, P
    LECLERCQ, Y
    GERBI, A
    BERREBIBERTRAND, I
    LELIEVRE, LG
    FEBS LETTERS, 1991, 281 (1-2): : 145 - 148
  • [23] Inhibition of the Na+/K+-ATPase by cardiac glycosides suppresses expression of the IDO1 immune checkpoint in cancer cells by reducing STAT1 activation
    Shandell, Mia A.
    Capatina, Alina L.
    Lawrence, Samantha M.
    Brackenbury, William J.
    Lagos, Dimitris
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2022, 298 (03)
  • [24] Binding domain of oligomycin on Na+,K+-ATPase
    Homareda, H
    Ishii, T
    Takeyasu, K
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 400 (2-3) : 177 - 183
  • [25] Role of Na+, K+-ATPase α1 subunit in the intracellular accumulation of cisplatin
    Shuichi Kishimoto
    Yuji Kawazoe
    Mako Ikeno
    Mizuha Saitoh
    Yukari Nakano
    Yuko Nishi
    Shoji Fukushima
    Yoshikazu Takeuchi
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 84 - 90
  • [26] Role of Na+,K+-ATPase α1 subunit in the intracellular accumulation of cisplatin
    Kishimoto, S
    Kawazoe, Y
    Ikeno, M
    Saitoh, M
    Nakano, Y
    Nishi, Y
    Fukushima, S
    Takeuchi, Y
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (01) : 84 - 90
  • [27] Epigallocatechin-3-gallate is an inhibitor of Na+,K+-ATPase by favoring the E1 conformation
    Ochiai, Hideo
    Takeda, Kazuo
    Soeda, Shiori
    Tahara, Yoshikazu
    Takenaka, Hitoshi
    Abe, Kazuhiro
    Hayashi, Yutaro
    Noguchi, Shunsuke
    Inoue, Masumi
    Schwarz, Silvia
    Schwarz, Wolfgang
    Kawamura, Masaru
    BIOCHEMICAL PHARMACOLOGY, 2009, 78 (08) : 1069 - 1074
  • [28] Roles of transmembrane segment M1 of Na+, K+-ATPase and Ca2+-ATPase, the gatekeeper and the pivot
    Einholm, Anja Pernille
    Andersen, Jens Peter
    Vilsen, Bente
    JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2007, 39 (5-6) : 357 - 366
  • [29] The α2 Na+/K+-ATPase isoform mediates LPS-induced neuroinflammation
    Leite, J. A.
    Isaksen, T. J.
    Heuck, A.
    Scavone, C.
    Lykke-Hartmann, K.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [30] A CASPR1-ATP1B3 protein interaction modulates plasma membrane localization of Na+/K+-ATPase in brain microvascular endothelial cells
    Zhang, Shu-Hong
    Liu, Dong-Xin
    Wang, Li
    Li, Yu-Hua
    Wang, Yan-Hua
    Zhang, Hu
    Su, Zheng-Kang
    Fang, Wen-Gang
    Qin, Xiao-Xue
    Shang, De-Shu
    Li, Bo
    Han, Xiao-Ning
    Zhao, Wei-Dong
    Chen, Yu-Hua
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (16) : 6375 - 6386